Cannabinoid type-1 (CB1) receptor inverse agonists improve type 2 diabetes and dyslipidaemia but were discontinued due to adverse psychiatric effects. delta9-Tetrahydrocannabivarin (THCV) is a neutral CB1 antagonist producing hypophagia and body weight reduction in lean mice. We investigated its effects in dietary-induced (DIO) and genetically (ob/ob) obese mice.
First some explanation
Dyslipidemia is an abnormal amount of lipids (e.g. cholesterol and/or fat) in the blood. In developed countries, most dyslipidemias are hyperlipidemias; that is, an elevation of lipids in the blood. This is often due to diet and lifestyle. Prolonged elevation of insulin levels can also lead to dyslipidemia.
Hypophagia is reduced food intake.
OK. How about THCV?
From The Weed Blog:
THCV is found in largest quantities in Cannabis sativa strains. It is currently being developed as a treatment for metabollic disorders including diabetes. THCV has been shown to block the psychoactive effects of THC.And this might also be helpful: Even More Science Suggesting That Cannabinoids May Halt Diabetes